Clinical TrialJul 28, 2026, 06:02 AM
ProMIS Neurosciences PMN310 Phase 1b Interim Results Show Favorable Safety
AI Summary
ProMIS Neurosciences announced positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial for PMN310 in Alzheimer's disease patients. The drug candidate demonstrated a favorable safety profile with no cases of amyloid-related imaging abnormalities-edema (ARIA-E) and early, directionally consistent movement in disease-relevant biomarkers. These results support PMN310's differentiated mechanism targeting toxic amyloid-beta oligomers, aiming to reduce ARIA risk. The company expects to release unblinded 12-month topline data, including efficacy, in the first quarter of 2027.
Key Highlights
- No ARIA-E observed across all genotypes, including APOE4 homozygotes, in 136 AD patients.
- 4.4% total ARIA (all mild and asymptomatic ARIA-H) reported at interim.
- 61% of patients were APOE4 carriers, with 11% being homozygotes.
- 68.5% of patients showed a decline in plasma pTau217 from baseline.
- 62.5% of patients showed a decline in CSF MTBR-tau243 from baseline.
- Topline 12-month results, including efficacy data, are expected in Q1 2027.
Price Impact
More from PMN